Carmell Therapeutics Stock Operating Margin
| CTCX Stock | 0.43 0.03 6.52% |
Carmell Therapeutics fundamentals help investors to digest information that contributes to Carmell Therapeutics' financial success or failures. It also enables traders to predict the movement of Carmell Stock. The fundamental analysis module provides a way to measure Carmell Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Carmell Therapeutics stock.
Carmell |
Carmell Therapeutics Company Operating Margin Analysis
Carmell Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Carmell Therapeutics Operating Margin | (96.71) % |
Most of Carmell Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Carmell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Carmell Therapeutics has an Operating Margin of -96.7116%. This is 175.69% higher than that of the Biotechnology sector and 146.02% higher than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Carmell Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Carmell Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Carmell Therapeutics could also be used in its relative valuation, which is a method of valuing Carmell Therapeutics by comparing valuation metrics of similar companies.Carmell Therapeutics is currently under evaluation in operating margin category among its peers.
Carmell Fundamentals
| Return On Equity | -1.76 | ||||
| Return On Asset | -0.85 | ||||
| Operating Margin | (96.71) % | ||||
| Current Valuation | 12.52 M | ||||
| Shares Outstanding | 30.12 M | ||||
| Shares Owned By Insiders | 33.66 % | ||||
| Shares Owned By Institutions | 19.49 % | ||||
| Number Of Shares Shorted | 680.21 K | ||||
| Price To Book | 1.91 X | ||||
| Price To Sales | 1,045 X | ||||
| Gross Profit | 12.03 K | ||||
| EBITDA | (15.19 M) | ||||
| Net Income | (15.45 M) | ||||
| Total Debt | 2.14 M | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | 0.48 X | ||||
| Beta | 0.31 | ||||
| Market Capitalization | 12.88 M | ||||
| Total Asset | 63.95 M | ||||
| Retained Earnings | (58.5 M) | ||||
| Working Capital | 24.4 M | ||||
| Net Asset | 63.95 M |
About Carmell Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Carmell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carmell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carmell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.